176 related articles for article (PubMed ID: 36446891)
1. Loss-of-function mutations of SOX17 lead to YAP/TEAD activation-dependent malignant transformation in endometrial cancer.
Wang M; Yan Q; Song Y; Zhang Z; Chen X; Gao K; Wan X
Oncogene; 2023 Jan; 42(4):322-334. PubMed ID: 36446891
[TBL] [Abstract][Full Text] [Related]
2. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
[TBL] [Abstract][Full Text] [Related]
3. p190A inactivating mutations cause aberrant RhoA activation and promote malignant transformation via the Hippo-YAP pathway in endometrial cancer.
Wen X; Wan J; He Q; Wang M; Li S; Jiang M; Qian Z; Liu B; Lu W; Wang K; Gao K; Wan X
Signal Transduct Target Ther; 2020 May; 5(1):81. PubMed ID: 32457342
[TBL] [Abstract][Full Text] [Related]
4. Identification of a derivative of the alkaloid emetine as an inhibitor of the YAP-TEAD interaction and its potential as an anticancer agent.
Sekine S; Takase S; Hayase R; Noritsugu K; Maemoto Y; Ichikawa Y; Ogawa K; Kondoh Y; Osada H; Yoshida M; Ito A
Biosci Biotechnol Biochem; 2023 Apr; 87(5):501-510. PubMed ID: 36809780
[TBL] [Abstract][Full Text] [Related]
5. SOX17 is a tumor suppressor in endometrial cancer.
Zhang Y; Bao W; Wang K; Lu W; Wang H; Tong H; Wan X
Oncotarget; 2016 Nov; 7(46):76036-76046. PubMed ID: 27738313
[TBL] [Abstract][Full Text] [Related]
6. Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers.
Luo M; Xu Y; Chen H; Wu Y; Pang A; Hu J; Dong X; Che J; Yang H
Eur J Med Chem; 2022 Dec; 244():114847. PubMed ID: 36265280
[TBL] [Abstract][Full Text] [Related]
7. CK2-induced cooperation of HHEX with the YAP-TEAD4 complex promotes colorectal tumorigenesis.
Guo Y; Zhu Z; Huang Z; Cui L; Yu W; Hong W; Zhou Z; Du P; Liu CY
Nat Commun; 2022 Aug; 13(1):4995. PubMed ID: 36008411
[TBL] [Abstract][Full Text] [Related]
8. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
Crawford JJ; Bronner SM; Zbieg JR
Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
[No Abstract] [Full Text] [Related]
9. YAP antagonizes TEAD-mediated AR signaling and prostate cancer growth.
Li X; Zhuo S; Cho YS; Liu Y; Yang Y; Zhu J; Jiang J
EMBO J; 2023 Feb; 42(4):e112184. PubMed ID: 36588499
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a new class of reversible TEA domain transcription factor inhibitors with a novel binding mode.
Hu L; Sun Y; Liu S; Erb H; Singh A; Mao J; Luo X; Wu X
Elife; 2022 Nov; 11():. PubMed ID: 36398861
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting of TEAD transcription factors in cancer.
Pobbati AV; Kumar R; Rubin BP; Hong W
Trends Biochem Sci; 2023 May; 48(5):450-462. PubMed ID: 36709077
[TBL] [Abstract][Full Text] [Related]
12. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy.
Pobbati AV; Han X; Hung AW; Weiguang S; Huda N; Chen GY; Kang C; Chia CS; Luo X; Hong W; Poulsen A
Structure; 2015 Nov; 23(11):2076-86. PubMed ID: 26592798
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and clinicopathological significance of TMEFF2, SMOC-2, and SOX17 expression in endometrial carcinoma.
Alabiad MA; Harb OA; Hefzi N; Ahmed RZ; Osman G; Shalaby AM; Alnemr AA; Saraya YS
Exp Mol Pathol; 2021 Oct; 122():104670. PubMed ID: 34339705
[TBL] [Abstract][Full Text] [Related]
15. Fluorescence polarization assay for the identification and evaluation of inhibitors at YAP-TEAD protein-protein interface 3.
Zhou W; Li Y; Song J; Li C
Anal Biochem; 2019 Dec; 586():113413. PubMed ID: 31479631
[TBL] [Abstract][Full Text] [Related]
16. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides.
Zhou Z; Hu T; Xu Z; Lin Z; Zhang Z; Feng T; Zhu L; Rong Y; Shen H; Luk JM; Zhang X; Qin N
FASEB J; 2015 Feb; 29(2):724-32. PubMed ID: 25384421
[TBL] [Abstract][Full Text] [Related]
17. YAP-TEAD up-regulates IRS2 expression to induce and deteriorate oesophageal cancer.
Xu X; Nie J; Lu L; Du C; Meng F; Song D
J Cell Mol Med; 2021 Mar; 25(5):2584-2595. PubMed ID: 33570213
[TBL] [Abstract][Full Text] [Related]
18. NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.
Garcia-Rendueles ME; Ricarte-Filho JC; Untch BR; Landa I; Knauf JA; Voza F; Smith VE; Ganly I; Taylor BS; Persaud Y; Oler G; Fang Y; Jhanwar SC; Viale A; Heguy A; Huberman KH; Giancotti F; Ghossein R; Fagin JA
Cancer Discov; 2015 Nov; 5(11):1178-93. PubMed ID: 26359368
[TBL] [Abstract][Full Text] [Related]
19. Targeting the YAP-TEAD interaction interface for therapeutic intervention in glioblastoma.
Saunders JT; Holmes B; Benavides-Serrato A; Kumar S; Nishimura RN; Gera J
J Neurooncol; 2021 Apr; 152(2):217-231. PubMed ID: 33511508
[TBL] [Abstract][Full Text] [Related]
20. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
